Browsing ICR Divisions by author "Spain, Lavinia"
Now showing items 1-13 of 13
-
Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma.
Lim, KHJ; Spain, L; Barker, C; Georgiou, A; Walls, G; et al. (ELSEVIER, 2018-02-01)BACKGROUND: Agreement on the utility of imaging follow-up in patients with high-risk melanoma is lacking. A UK consensus statement recommends a surveillance schedule of CT or positron-emission tomography-CT and MRI brain ... -
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome".
Spain, L; Larkin, J; Martin-Liberal, J (SPRINGER, 2016-06-01) -
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; et al. (CELL PRESS, 2018-04-19)The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ... -
Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series.
Spain, L; Walls, G; Messiou, C; Turajlic, S; Gore, M; et al. (SPRINGER, 2017-01-01)BACKGROUND: The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant ... -
Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features.
Spain, L; Schmid, T; Gore, M; Larkin, J (ELSEVIER SCI LTD, 2017-04-01) -
Exploring novel approaches to metastatic heterogeneity and clonal evolution
Turajlic, S; Spain, L (Institute of Cancer Research (University Of London), 2021-12-31)Background Alternative methods are required to optimise the clinical insights that may be derived from studies of cancer evolution and heterogeneity. Profiling a single biopsy of tumour tissue underestimates potential ... -
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas, F; Furness, AJS; Litchfield, K; Joshi, K; Rosenthal, R; et al. (CELL PRESS, 2018-04-09)With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion ... -
How we treat neurological toxicity from immune checkpoint inhibitors.
Spain, L; Tippu, Z; Larkin, JM; Carr, A; Turajlic, S (ELSEVIER, 2019-07-01)Neurological adverse events from immune checkpoint inhibition are increasingly recognised, especially with combination anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) and anti-programmed death receptor 1 (anti-PD-1) therapies. ... -
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
Spain, L; Walls, G; Julve, M; O'Meara, K; Schmid, T; et al. (OXFORD UNIV PRESS, 2017-02-01)BACKGROUND: Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved following large Phase ... -
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
Morganstein, DL; Lai, Z; Spain, L; Diem, S; Levine, D; et al. (WILEY, 2017-04-01)CONTEXT: Checkpoint inhibitors are emerging as important cancer therapies but are associated with a high rate of immune side effects, including endocrinopathy. OBJECTIVE: To determine the burden of thyroid dysfunction in ... -
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.
Mitchell, TJ; Turajlic, S; Rowan, A; Nicol, D; Farmery, JHR; et al. (CELL PRESS, 2018-04-19)Clear cell renal cell carcinoma (ccRCC) is characterized by near-universal loss of the short arm of chromosome 3, deleting several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with ... -
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.
Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Chambers, T; et al. (CELL PRESS, 2018-04-19)Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with ... -
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain, L; Larkin, J (FUTURE MEDICINE LTD, 2016-06-01)